Weekly Chart for ABUSIt seems ABUS is preparing for a big move. Weekly Chart is strong, over the 200w,100w and 50w MAV
−0.438USD
−72.85 MUSD
18.14 MUSD
137.52 M
About ARBUTUS BIOPHARMA CORP NPV
Sector
CEO
Michael J. McElhaugh
Headquarters
Warminster
Website
Employees (FY)
73
Founded
2005
ISIN
CA03879J1003
FIGI
BBG00Z1WRM11
Arbutus Biopharma Corp. is a clinical-stage biopharmaceutical company, which engages in developing novel therapeutics that target specific viral diseases. It focuses on the Hepatitis B virus, SARS-CoV-2, and other coronaviruses. The company was founded on October 6, 2005 and is headquartered in Warminster, PA.
ABUS - Breakout AttemptAttempting to breakout of a large down channel
Price has already moved out of it.
Bars pattern placed shows my thoughts of a spike out of the down channel and the bulls taking control.
If this does not occur assume bear control still in play.
POTENTIAL BULLISHPrice is currently squeezing, with a 50/50 chance of breaking above or below. So, all we have to do now is wait for a bullish candle to appear and break above USD4.50 with strong bullish momentum as a final confirmation.
ABUS - Similarities to Prior RunIn this post various similarities are displayed, corresponding to the same color
Both double bottoms on 1.618 (in yellow)
Both tops at 1.618 (in red)
The positioning above the 200 day moving average as of current is also an extremely bullish sign
ABUS about to go up due to Patent on MRNA... Interesting... Lets hope there is news release.. I don't know for certain if its only the patent news but I am confident on my TA. DO your own DD!
short analysisBecause of the convergence we see in the chart and the RSI, and the gray support range that indicates the fall to that range has not been seen, we will probably see that the chart experiences some re-fall. If the pull back up, we will have price growth up to the gray resistance range. And God knows
#ABUS to 4.91 Climbing to New Target by 16%Sector: Health Technology
Industry: Biotechnology
Arbutus Biopharma Corp. is a biopharmaceutical company. It engages in discovering, developing and commercializing a cure for patients suffering from chronic Hepatitis B virus infection. The company was founded in 2007 and is headquartered in Warmins
ABUS - LongABUS CMP - $4.38
Looking bullish in higher time frame. One can go for Positional Trade Setup with the following entry, exit & targets.
Buy Range $3.90 - $4 ONLY / Stop Loss $2.95
Target 1 - $5
Target 2 - $7
Target 3 - $9
Disclaimer: This is my view and for educational purpose only.
See all ideas
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of 0SGC is 2.746 USD — it has decreased by 4.75% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on LSE exchange ARBUTUS BIOPHARMA CORP NPV stocks are traded under the ticker 0SGC.
ARBUTUS BIOPHARMA CORP NPV is going to release the next earnings report on May 2, 2024. Keep track of upcoming events with our Earnings Calendar.
0SGC stock is 4.99% volatile and has beta coefficient of 0.67. Check out the list of the most volatile stocks — is ARBUTUS BIOPHARMA CORP NPV there?
One year price forecast for ARBUTUS BIOPHARMA CORP NPV has a max estimate of 5.000 USD and a min estimate of 4.000 USD.
0SGC earnings for the last quarter are −0.12 USD per share, whereas the estimation was −0.11 USD resulting in a −7.14% surprise. The estimated earnings for the next quarter are −0.12 USD per share. See more details about ARBUTUS BIOPHARMA CORP NPV earnings.
ARBUTUS BIOPHARMA CORP NPV revenue for the last quarter amounts to 4.66 M USD despite the estimated figure of 4.75 M USD. In the next quarter revenue is expected to reach 4.78 M USD.
Yes, you can track ARBUTUS BIOPHARMA CORP NPV financials in yearly and quarterly reports right on TradingView.
0SGC stock has fallen by 8.04% compared to the previous week, the month change is a 8.28% rise, over the last year ARBUTUS BIOPHARMA CORP NPV has showed a 8.86% decrease.
0SGC net income for the last quarter is −19.31 M USD, while the quarter before that showed −20.10 M USD of net income which accounts for 3.94% change. Track more ARBUTUS BIOPHARMA CORP NPV financial stats to get the full picture.
Today ARBUTUS BIOPHARMA CORP NPV has the market capitalization of 491.88 M, it has increased by 22.62% over the last week.
No, 0SGC doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, 0SGC shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade ARBUTUS BIOPHARMA CORP NPV stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 19, 2024, the company has 73.00 employees. See our rating of the largest employees — is ARBUTUS BIOPHARMA CORP NPV on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So ARBUTUS BIOPHARMA CORP NPV technincal analysis shows the sell today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating ARBUTUS BIOPHARMA CORP NPV stock shows the buy signal. See more of ARBUTUS BIOPHARMA CORP NPV technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on ARBUTUS BIOPHARMA CORP NPV future price: according to them, 0SGC price has a max estimate of 5.00 USD and a min estimate of 4.00 USD. Read a more detailed ARBUTUS BIOPHARMA CORP NPV forecast: see what analysts think of ARBUTUS BIOPHARMA CORP NPV and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. ARBUTUS BIOPHARMA CORP NPV EBITDA is −76.63 M USD, and current EBITDA margin is −422.41%. See more stats in ARBUTUS BIOPHARMA CORP NPV financial statements.